Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study

被引:35
作者
Causse, X
Payen, JL
Izopet, J
Babany, G
Girardin, MFS
机构
[1] Toulouse Univ Hosp, Toulouse, France
[2] Lyon Univ Hosp, Lyon, France
[3] Nice Univ Hosp, Nice, France
[4] Pau Gen Hosp, Pau, France
[5] Villeneuve St Georges Gen Hosp, Villeneuve St Georges, France
[6] Broussais Univ Hosp, Paris, France
[7] Bordeaux Pessac Univ Hosp, Bordeaux, France
[8] Tours Univ Hosp, Tours, France
[9] Creteil Univ Hosp, Creteil, France
[10] Metz Reg Hosp, Metz, France
[11] Besancon Univ Hosp, Besancon, France
[12] Grenoble Univ Hosp, Grenoble, France
[13] Rothschild Univ Hosp, Paris, France
[14] Cochin Univ Hosp, Paris, France
[15] Rennes Univ Hosp, Rennes, France
[16] Beaujon Univ Hosp, Paris, France
[17] Strasbourg Univ Hosp, Strasbourg, France
[18] Compiegne Gen Hosp, Amiens, France
[19] Marseille Univ Hosp, Marseille, France
[20] CBMS, Paris, France
[21] ACTGene Evry, Evry, France
[22] Orleans Reg Hosp, Orleans, France
关键词
chronic hepatitis C; hepatitis C virus; HIV infection; human immunodeficiency virus; interferon treatment;
D O I
10.1016/S0168-8278(00)80105-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim: The aim of this prospective study was to compare the response to alfa-interferon treatment of chronic hepatitis C in two groups of patients: coinfected with human immunodeficiency virus (HIV) (G I) or not (G II). Methods: One hundred and fifty-three patients with chronic hepatitis C had been enrolled in 30 French liver units or infectious diseases units between May 1992 and January 1995 (G I: 76, G II: 77) to receive alfa-2a interferon: 3 MU thrice weekly for 6 months. Results: One hundred and twenty-seven patients (G I: 63, G II: 64) fulfilled all criteria for analysis. The two groups were comparable for all demographic data, while significantly more severe biological and histological (p=0.001) parameters attested to more serious hepatitis among HIV-HCV coinfected patients. HCV viremia was higher among HIV-coinfected patients (p=0.0169), while genotype repartition was identical among the two groups (more than 52% of genotype 1, more than 31% of genotype 3). ALT normalization was, respectively, (G I/G II) obtained in 17.46%/26.56% (not significant) of patients at the end of treatment and in 11.11%/12.5% (not significant) of patients after 6 months of follow-up. In a multivariate analysis, GGT level before therapy (relative risk 2.1, confidence interval 1.1-5.8) and body surface area (relative risk 1.9, confidence interval 1.1-3.7) were the variables independently associated with the response to alfa-interferon treatment (higher GGT and more elevated body surface area were associated With a risk of non-response). Conclusion: In our study HIV infection did not affect the alfa-interferon treatment response of chronic hepatitis C, and response could be achieved among HIV-coinfected patients. Present therapeutic anti-HCV schedules need to be proposed to HIV-HCV coinfected patients before severe immunosuppression occurs. On the other hand, more severe biological and histological parameters were observed among HIV-HCV coinfected patients, which suggests a need to study whether HIV infection is associated with a worsening course of chronic hepatitis C.
引用
收藏
页码:1003 / 1010
页数:8
相关论文
共 49 条
  • [1] RECOMBINANT INTERFERON-ALPHA FOR CHRONIC HEPATITIS-C IN PATIENTS POSITIVE FOR ANTIBODY TO HUMAN-IMMUNODEFICIENCY-VIRUS
    BOYER, N
    MARCELLIN, P
    DEGOTT, C
    DEGOS, F
    SAIMOT, AG
    ERLINGER, S
    BENHAMOU, JP
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (04) : 723 - 726
  • [2] Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24): : 1962 - 1969
  • [3] COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS
    CAUSSE, X
    GODINOT, H
    CHEVALLIER, M
    CHOSSEGROS, P
    ZOULIM, F
    OUZAN, D
    HEYRAUD, JP
    FONTANGES, T
    ALBRECHT, J
    MESCHIEVITZ, C
    TREPO, C
    [J]. GASTROENTEROLOGY, 1991, 101 (02) : 497 - 502
  • [4] [Anonymous], 1992, MMWR Recomm Rep, V41, P1
  • [5] HIGH HEPATITIS-C VIREMIA AND IMPAIRED ANTIBODY-RESPONSE IN PATIENTS COINFECTED WITH HIV
    CRIBIER, B
    REY, D
    SCHMITT, C
    LANG, JM
    KIRN, A
    STOLLKELLER, F
    [J]. AIDS, 1995, 9 (10) : 1131 - 1136
  • [6] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
    DAVIS, GL
    BALART, LA
    SCHIFF, ER
    LINDSAY, K
    BODENHEIMER, HC
    PERRILLO, RP
    CAREY, W
    JACOBSON, IM
    PAYNE, J
    DIENSTAG, JL
    VANTHIEL, DH
    TAMBURRO, C
    LEFKOWITCH, J
    ALBRECHT, J
    MESCHIEVITZ, C
    ORTEGO, TJ
    GIBAS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1501 - 1506
  • [7] DAVIS GL, 1990, HEPATOLOGY, V12, P905
  • [8] Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial
    Degos, F
    Daurat, V
    Chevret, S
    Gayno, S
    Bastie, A
    Riachi, G
    Batolomei-Portal, I
    Barange, K
    Moussalli, J
    Naveau, S
    Bailly, F
    Chaumet-Riffaud, P
    Chastang, C
    [J]. JOURNAL OF HEPATOLOGY, 1998, 29 (02) : 224 - 232
  • [9] RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DIBISCEGLIE, AM
    MARTIN, P
    KASSIANIDES, C
    LISKERMELMAN, M
    MURRAY, L
    WAGGONER, J
    GOODMAN, Z
    BANKS, SM
    HOOFNAGLE, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1506 - 1510
  • [10] A formula to estimate the approximate surface area if height and weight be known
    Du Bois, D
    Du Bois, EF
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1916, 17 (06) : 863 - 871